Chan CW, et al. - The cardiovascular risk of various anti-diabetic agent (ADA) used as add-on medication to metformin was examined in type 2 diabetes (T2DM) patients from a nationwide cohort. Findings suggested that compared with sulphonylureas (SU) added to metformin, both thiazolidinediones (TZD) and alpha-glucosidase inhibitors (AGI), when used as an add-on drug to metformin were associated with lower major adverse cardiovascular event risk in this retrospective cohort study.